The Analysis of the Effective Systemic Lidocaine Dosage on the Expression of HMGB1 mRNA on Mice with Sterile Musculoskeletal Injury

Sirait, Robert Hotman; Hatta, Mochammad; Ramli, Muhammad Isran; Simanjuntak, Tigor Peniel; Suprayogi, Bambang; Islam, Andi Asadul; Arief, Syafri Kamsul

doi:10.4236/ojanes.2017.72004

Cited by 5 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravenously administered lidocaine can be used for transcription inhibition of HMGB1 mRNA expression and TLR4 protein translation in sterile inflammation of mice [ 4 ]. In the sublining layer of joints in rheumatoid arthritis and osteoarthritis.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies revealed that HMGB1 has molecular impact in Pathogen-Associated Molecular Patterns (PAMPs) in infection and Damage-Associated Molecular Patterns (DAMPs) in injury [ 3 ]. Previous studies showed that HMGB1 has involved in molecular mechanisms of systemic lidocaine treatment for closed fracture musculoskeletal injury in animal model [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunomodulatory properties of high mobility group box 1 and its potential role in brain injury: Review article

Tommy

Islam

Hatta

et al. 2020

Annals of Medicine and Surgery

Self Cite

View full text Add to dashboard Cite

Background Human mobility group box 1 (HMGB1) is a novel biomolecular agent which has a major part in inflammation process. HMGB1 has been known to be a strong pro-inflammatory factor as damage associated molecular pattern (DAMP) which its interaction with its receptor, the receptor of advanced glycation end products (RAGE), will cause positive amplification of inflammation signalling pathway. Brain injury is one of the major contributors for disability and death which neuroinflammation has a major role in its pathogenesis and influencing its outcome. In neuroinflammation, it has been described that HMGB1 may have a pivotal role in the process. Objective The objective of this article is to review the role HMGB1 in brain injury and its immunomodulatory properties. Methods A comprehensive search of literature was conducted in PubMed (NIH), Scopus, EMBASE, and Google Scholar database using keyword combinations of the medical subject headings (MeSH) of “HMGB1” and “Brain Injury” and relevant reference lists were also manually searched. All relevant articles of any study design published from year 1990 till June 2020, were included and narratively discussed in this review. Results Twenty-four articles were shortlisted and reviewed in this article. Through these articles, we synthesis information on the function and metabolism of HMGB1, immunomodulatory effect of HMGB1, clinical findings and other potential treatment involving HMGB1, and role of HMGB1 protein in brain injury. Conclusion HMGB1 has a strong pro-inflammation property which predominantly acts through RAGE pathways.Review registration number reviewregistry966 in www.researchregistry.com .

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immunomodulatory properties of high mobility group box 1 and its potential role in brain injury: Review article

Tommy

Islam

Hatta

et al. 2020

Annals of Medicine and Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our result shows that intravenous administration of 2 mg/kg lidocaine effectively inhibited transcription of HMGB1 mRNA expression in BALB/c mice with a closed fracture musculoskeletal injury. [ 20 ] The increased HMGB1 protein levels decreased from 1819.66 ± 239.50 to 417.00 ± 222.86 after lidocaine therapy for 24 h, showing that intravenous administration of 2 mg/kg of lidocaine was effective in suppressing the translation of HMGB1 protein content in BALB/c mice with a closed fracture musculoskeletal injury. [ 20 21 22 ] The initial HMGB1 protein level was slightly higher than the level after 24 h of systemic lidocaine therapy, but the difference was not statistically significant.…”

Section: Discussionmentioning

confidence: 99%

Systemic lidocaine inhibits high-mobility group box 1 messenger ribonucleic acid expression and protein in BALB/c mice after closed fracture musculoskeletal injury

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background:Severe musculoskeletal trauma can trigger an inflammatory response, and an excessive inflammatory response can lead to systemic inflammatory response syndrome and multiorgan failure. High-mobility group box 1 (HMGB1) is an early mediator pro-inflammatory cytokine in sterile injuries and a late cytokine mediator in infection and sepsis. Previous research has shown that administration of systemic lidocaine can inhibit HMGB1 expression in macrophages of septic rats. The aim of this study was to demonstrate the efficacy of systemic lidocaine to inhibit HMGB1 mRNA and protein in a BALB/c mouse model of sterile inflammation due to closed fracture musculoskeletal injury.Materials and Methods:Twenty adult male BALB/c mice were divided into lidocaine and control groups. The closed fracture musculoskeletal injury was performed by breaking the left thigh bone of the mice. Four hours after undergoing the closed fracture, the lidocaine group was treated with lidocaine intravenous (2 mg/kg). The same volume of distilled water was injected into the control group instead of lidocaine. HMGB1 mRNA expression was examined with real-time polymerase chain reaction, and HMGB1 protein level was determined with enzyme-linked immunosorbent assay.Results:The expression of HMGB1 mRNA and protein levels in mice that sustained inflammation due to a closed fracture musculoskeletal injury was significantly decreased in the lidocaine group (P < 0.00 and P < 0.00 for mRNA and protein, respectively).Conclusions:Intravenous administration of lidocaine effectively inhibited the inflammatory process in BALB/c mice that underwent closed fracture musculoskeletal injury by suppressing HMGB1 mRNA transcription and HMGB1 protein translation.

show abstract

“…Our results show that 2 mg/kgBW lidocaine administration inhibits transcription of HMGB1 mRNA expression and translation of TLR4 protein in sterile injury BALB/c mice with sterile injury. 16,17 Previously, Hollmann MW et al have shown that amide groups local anesthesia inhibited release of inflammatory mediators leukotrin B4 and interleukin-1 from human neutrophils and monocytes. 8 In a previous reasearch, Wang HL et al demonstrated that administration of systemic lidocaine inhibits release of HMGB1 septic mice which induced with lypopolysaccharide 10 and transcription of mRNA HMGB1 in patients during histerectomy.…”

Section: Discussionmentioning

confidence: 99%

Profile of HMGB1 mRNA Expression and TLR4 Protein in BALB/c Mice Model Sterile Injury after Systemic Lidocaine Administration

Sirait¹,

Hatta²,

Arief³

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: High mobility group box 1 (HMGB1) is a cytokine proinflamation which contributes to inflammation. HMGB1 physically interacts with toll like receptor 4 (TLR4) to release macrophage cytokines. The aim of this study was to demonstrate the effectiveness of systemic lidocaine administration to inhibit the expression of HMGB1 mRNA and TLR4 protein in mice BALB/c mice with sterile injury. Material and Methods: Twenty adult male BALB/c mice were divided into lidocaine and control groups. A sterile injury is done by closed fracturing the left thigh bone of the mice. The lidocaine group was treated with 2 mg/kgBW lidocaine through tail vein injection after 4 h of sterile injury. The control group was given distilled water therapy as a substitute for lidocaine. Mice blood is extracted from the tail vein before trauma, 4 h after trauma, and 2 h after the administration of lidocaine and distilled water is complete. The HMGB1 mRNA expression was examined by quantitative real-time polymerase chain reaction (qPCR) while the TLR4 protein level was determined with enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions. Result: The HMGB1 mRNA expression and TLR4 protein levels in BALB/c that sustained inflammation due to a sterile injury was significantly decreased in the lidocaine group (p < 0.00). Conclusion: Administration systemic 2 mg/kgBW of lidocaine is effectively inhibits HMGB1 mRNA and TLR4 protein in mice that sustain inflammation due to a sterile injury.

show abstract

The Analysis of the Effective Systemic Lidocaine Dosage on the Expression of HMGB1 mRNA on Mice with Sterile Musculoskeletal Injury

Cited by 5 publications

References 25 publications

Immunomodulatory properties of high mobility group box 1 and its potential role in brain injury: Review article

Immunomodulatory properties of high mobility group box 1 and its potential role in brain injury: Review article

Systemic lidocaine inhibits high-mobility group box 1 messenger ribonucleic acid expression and protein in BALB/c mice after closed fracture musculoskeletal injury

Profile of HMGB1 mRNA Expression and TLR4 Protein in BALB/c Mice Model Sterile Injury after Systemic Lidocaine Administration

Contact Info

Product

Resources

About